NCT05912244 2026-02-17A Study of IO102/IO103, Nivolumab, and Relatlimab in People With MelanomaMemorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting43 enrolled
NCT06101134 2025-04-14A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsBristol-Myers SquibbPhase 2 Active not recruiting100 enrolled